Table of Contents
antibiotics for Rx of Staph. aureus
beta lactamase resistant penicillins
- penicillins combined with beta lactamase inhibitors such as clavulanic acid, sulbactam, tazobactam
- eg. amoxycillin with clavulanic acid (Augmentin Duo Forte)
- quinolones such as ciprofloxacin
- MRSA contains a gene, mecA, which stops β-lactam antibiotics from inactivating the enzymes (transpeptidases) that are critical to cell wall synthesis
- use of fluoroquinolones is associated with significantly increased risk of colonisation with MRSA
- community acquired MRSA is a hybrid of hospital MRSA and community Staph and tends to be more virulent, although easier to treat than hospital MRSA
- CA-MRSA may respond to co-trimoxazole, tetracyclines or clindamycin but is usually treated with vancomycin
- a structural congener of vancomycin that has a similar activity spectrum but a longer half-life
vancomycin intermediate-resistant Staphylococcus aureus (VISA)
- This antibiotic is not effective for left-sided endocarditis, or for pneumonia because it binds to surfactant and is inactivated.
- The efficacy of daptomycin in patients with prosthetic heart valves has not been demonstrated.
- see also Australian Prescriber article
antibiotics_staph.txt · Last modified: 2012/01/09 02:59 by 127.0.0.1